Cencora: Cencora is expected to report a moderate performance for the fiscal second quarter following a strong start earlier in the year. The U.S. Healthcare Solutions segment is likely to continue benefiting from robust demand for specialty distribution and GLP-1 drugs, with a forecasted 14% revenue growth to $74 billion and a 10% increase in operating income. The company's strategic acquisitions, including Retina Consultants of America in January, should further contribute to revenue growth. However, a decline in COVID-19 vaccine sales may impact both segmental sales and margins, with softer growth expected in GLP-1 drug sales compared to the first quarter's 53% year-over-year increase.